[ad_1]
With the aim of knowing the most recent data on the treatment of schizophrenia, Angelini Pharma Spain organized a digital meeting called Clinical data of Lurasidone and real-world evidence in schizophrenia, which allowed to publicize the most recent clinical data on Lurasidone and to share the experience of the actual use of the product in patients with severe mental illness. The meeting saw the participation of the main world opinion leaders in this field, such as Leslie Citrome, Philip D. Harvey and Eduard Vieta.
According to Dr. Leslie Citrome of New York Medical College (Valhalla, New York), in her experience with Lurasidone over the past 10 years, it is “an effective drug that is also effective in real life. It reduces the symptoms of schizophrenia and at the same time is very well tolerated by patients with schizophrenia ”. Citrome explained that it usually prescribes it in its highest dose, “160 mg / day, particularly in those patients who do not respond as well as would be expected at 80 mg / day.” Citrome notes that there is evidence from clinical trials to support this choice and notes that the side effects are reduced: “I know I will often find no weight gain, at least compared to my experience with other second generation antipsychotics,” he adds.
For his part, Dr. Philip D. Harvey, expert in neurocognition and functional recovery, points out that “Lurasidone is a non-sedative compound that does not have anticholinergic properties. Consequently, compared to other atypical antipsychotics, it has a very beneficial cognitive profile. This cognitive profile is likely to translate into better daily functioning, which is actually the essence of effectiveness in treating people with schizophrenia. “On the other hand, the specialist states that” the lack of weight gain associated with ‘taking Lurasidone has other important implications, as the development of type 2 diabetes is damaging to the brain and is associated with the cognitive changes themselves “.
To achieve the best response in patients, Eduard Vieta, professor of psychiatry at the University of Barcelona and head of the Department of Psychiatry at Hospital Clínic, points out that “Lurasidone is an option in the treatment of schizophrenia that also provides benefits in affective symptoms. and cognitive. Thanks to its tolerability profile, it is an excellent drug to transfer some patients from other treatments with questionable tolerability to Lurasidone, an effective treatment that has better tolerability while preserving the efficacy of the initial drug “. To achieve the best efficacy, the professor states that “it is important to take into account the previous drug profile and the Lurasidone profile to maximize the benefits of the change process.”
All these data on the use of Lurasidone in patients with schizophrenia, from different studies, were presented in the webinar organized by Angelini Pharma Spain. Interested professionals can retrieve the content at this link.
Olga Insua, Country Manager of Angelini Pharma Spain explains that “we have a firm commitment to the environment and that is why We believe that the patient, together with the healthcare worker, should be at the center of our business with the joint goal of improving their quality of life. Furthermore, we are always alongside professionals and therefore we want to provide them with access to scientific information and the most up-to-date knowledge to help them in the development of their business ”, he concludes.
On schizophrenia
Schizophrenia, according to the WHO, is a serious mental disorder that affects more than 21 million people around the world and is characterized by a distortion of thinking, perceptions, emotions, language, self-awareness and conduct. Some of the most common experiences are hallucinations (hearing voices or seeing things that don’t exist) and delusions (persistent and erroneous beliefs). People with schizophrenia are 2 to 2.5 times more likely to die at a young age than the population as a whole. This is usually due to physical diseases, such as cardiovascular, metabolic and infectious diseases. Further, people with schizophrenia often experience stigmatization, discrimination and violation of their human rights.
Angelini Pharma
Angelini Pharma is committed to constantly giving hope to patients with a focus on mental health, including pain, rare diseases and consumer health. Angelini Pharma is an integrated company, with extensive and recognized research and development programs, production facilities World class and international marketing activities for market-leading active ingredients and medicines. For more information, visit www.angelinipharma.com.
This content was developed by UE Studio, Unidad Editorial’s creative branded content and content marketing company, for Angelini Pharma.
Source link
